PCVX - NASDAQ

Vaxcyte, Inc.

PCVX·NASDAQ

$47.70

+1.1%

HealthcareBiotechnology

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$6.89B

EPS-5.6300

P/E Ratio-8.47

Earnings Date08/05/2026

pcvx

Cash at Beginning of Period

Last Annual Value

389.19M

3-Year CAGR

77%

5-Year CAGR

46%

10-Year CAGR

193%

Adjust for Inflation

Vaxcyte, Inc. Competitors Analysis of Cash at Beginning of Period

PCVX · NASDAQ

Company	Cash at Beginning of Period	CAGR 3Y	CAGR 5Y	CAGR 10Y
Vaxcyte, Inc. NASDAQ:PCVX	389.19M	-22.5%	0.2%	N/A
Alkermes plc NASDAQ:ALKS	291.15M	-0.2%	1.3%	4.9%
Metsera, Inc. NASDAQ:MTSR	75.19M	71.2%	N/A	N/A
Arcellx, Inc. NASDAQ:ACLX	108.31M	17.5%	18.3%	N/A
Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR	102.69M	-1.7%	-6.5%	2.4%
TG Therapeutics, Inc. NASDAQ:TGTX	181.19M	20.5%	-20.1%	12.6%
Akero Therapeutics, Inc. NASDAQ:AKRO	234.21M	-2.1%	4.6%	N/A
Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX	265.85M	98.5%	23.2%	31.0%
Krystal Biotech, Inc. NASDAQ:KRYS	344.87M	28.7%	5.2%	N/A
PTC Therapeutics, Inc. NASDAQ:PTCT	779.71M	38.1%	29.2%	29.7%

Vaxcyte, Inc. Fair Value Envelope

PCVX · NASDAQ

Our analysis suggests that PCVX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.7, this represents a potential HIDDEN relative to our calculated worth for Vaxcyte, Inc..

HIDDEN

Intrinsic Value

Current Price: $47.7

Related Guides

Blog Categories

Continue your PCVX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.